Latest News - Novartis

Monday, February 19, 2018

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The generic drug business has faced some struggles of recent amid that decline Swiss pharmaceutical company Novartis AG (NVS - Get Report) is reportedly gearing up to launch a sale process for its U.S…

Read the full story

Thursday, January 25, 2018

Novartis Licenses Spark Therapeutics' Gene Therapy in All Markets Outside the US

Novartis announced a licensing agreement with Spark Therapeutics covering development, registration, and commercialization rights to voretigene neparvovec in markets outside the United States. Voretig…

Read the full story

Wednesday, January 24, 2018

Novartis Poised for Growth as CEO Hands Baton to U.S. Newcomer

Novartis expects to return to operating profit growth this year, with new Chief Executive Vas Narasimhan inheriting the Swiss drugmaker just as revenue from its latest medicines accelerates and the im…

Read the full story

Monday, November 13, 2017

Novartis: Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity in nAMD

Novartis announced further positive results from two phase 3 studies of brolucizumab versus aflibercept (Eylea). Results showed noninferiority in primary endpoint, superiority in key retinal health ou…

Read the full story

Tuesday, November 07, 2017

Novartis Pivotal Brolucizumab (RTH258) Data to be Presented at AAO

Novartis will be presenting more detailed results from its phase 3 studies (HAWK and HARRIER) of brolucizumab (RTH258) vs. aflibercept for the treatment of neovascular age-related macular degeneration…

Read the full story

Monday, October 30, 2017

Novartis to buy Advanced Accelerator Applications for $3.9 billion

Novartis announced Monday plans to buy Advanced Accelerator Applications for $3.9 billion in cash, strengthening the company's oncology portfolio. Under the deal, Novartis will gain Advanced Accel…

Read the full story

Monday, September 04, 2017

Novartis CEO Joseph Jimenez to Retire Next Year; Vasant Narasimhan Named as Replacement

Novartis announced Monday that CEO Joseph Jimenez will step down from his role effective January 31, 2018, to be replaced by Vasant Narasimhan, the company's current global head of drug developmen…

Read the full story

Tuesday, June 20, 2017

Novartis RTH258 (Brolucizumab) Demonstrates Robust Visual Gains in Wet AMD Patients with a Majority on a 12-week Injection Interval

Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two phase 3 studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These …

Read the full story

Wednesday, April 12, 2017

Commentary: Novartis Finds Its Next Mass-Market Ophthalmology Drug Candidate at a Small Virtual Biotech With a Global View

Like me, you may never have heard about Lubris BioPharma before today. But Novartis has. And that is by far more important. Today the pharma giant reached out and exercised an option on a recombinant …

Read the full story

Wednesday, January 25, 2017

Novartis Considers Spinning Off Alcon Unit

Novartis said it is considering several options for its Alcon unit, including the possibility of separating from the eye care division. The announcement comes after Novartis reported that Alcon’…

Read the full story

Wednesday, January 18, 2017

Novartis CEO: Trump Could Boost Economy but Obamacare Needs to be Replaced if Repealed

Donald Trump's policies could be good for the economy but Obamacare should be replaced if it's repealed, the CEO of drug giant Novartis told CNBC on Tuesday. Joseph Jimenez played down some of…

Read the full story

Tuesday, December 20, 2016

Novartis Bolsters Ophthalmology Pipeline Through Acquisition of Encore Vision

Novartis announced that it has entered into a definitive agreement to acquire Encore Vision, a company focused on the development of a novel treatment in presbyopia. Terms of the deal were not disc…

Read the full story

Monday, November 21, 2016

Novartis Backs Off From 2016 Date for Testing Google Autofocus Lens

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadil…

Read the full story

Friday, October 14, 2016

Lucentis Recommended by CHMP for EU Approval in Sixth Indication for the Treatment of Visually Impaired Patients

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal ne…

Read the full story

Thursday, September 01, 2016

Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions

Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatm…

Read the full story
Load More